Joan Carles

10PUBLICATIONS
143CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical devicesPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 02, 2025
Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer.

Julian Brandariz, Lara de Llobet, Victor Esquefa

|Aug 21, 2024
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.

Sara Santagata, Anna Maria Trotta, Crescenzo D'Alterio

|Jun 20, 2023
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer.

David Pook, Daniel M Geynisman, Joan Carles

|May 24, 2023
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.

Joan Carles, Rafael A Medina-Lopez, Javier Puente

|Aug 02, 2022
A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma.

Raffaella Iurlaro, Inja Waldhauer, Ester Planas-Rigol

Pageof 2